VolitionRx Limited (NYSEMKT:VNRX) has presented data at the World Congress of GI Endoscopy 2017 conference in Hyderabad, India, from a study that confirms prior test results that the Nu.QTM Colorectal Cancer Screening Triage test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection.
“This is a key clinical milestone in the launch of our Nu.QTM Triage product. This validation study, in a second population of 1,961 subjects, greatly assists us with sales and marketing efforts in the EU and Asia,” said Louise Day, Chief Marketing and Communications Officer at VolitionRx.
The lead author of the study, Dr. Marielle Herzog, commented, “This data confirms the role that the Nu.QTM Triage test can play in accelerating the diagnosis of colorectal cancer.”
Story by ProactiveInvestors